Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

NCT06434090 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Liposomal irinotecan
DRUG: Bevacizumab

Sponsor

Sun Yat-sen University